Showing results (151-160 of 214) with videos related to
Sort By:
Pageof 22
Biochemical Pharmacology|October 24, 1991
The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)A L Jackman, D R Newell, W Gibson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activityP G Smith, H D Thomas, H C Barlow, et al.European Journal of Cancer (Oxford, England : 1990)|November 7, 2003
Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trialsG Atalay, L Biganzoli, F Renard, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 daysA N Hughes, I Rafi, M J Griffin, et al.Gynecologic Oncology|September 24, 2004
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancerA Clamp, M Adams, R Atkinson, et al.British Journal of Cancer|March 1, 1995
The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancerM J Lind, L Gumbrell, B M Cantwell, et al.Journal of Medicinal Chemistry|June 1, 1986
Quinazoline antifolates inhibiting thymidylate synthase: variation of the amino acidT R Jones, M J Smithers, R F Betteridge, et al.Journal of Medicinal Chemistry|November 1, 1990
Quinazoline antifolate thymidylate synthase inhibitors: 2'-fluoro-N10-propargyl-5,8-dideazafolic acid and derivatives with modifications in the C2 positionA L Jackman, P R Marsham, T J Thornton, et al.Cancer Chemotherapy and Pharmacology|August 8, 2001
Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancerA V Boddy, M J Griffin, J Sludden, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1995
Cancer Research Campaign phase II trial of temozolomide in metastatic melanomaN M Bleehen, E S Newlands, S M Lee, et al.Pageof 22